Contact
searchSearch
HMP Global
Login

Brain Cancer Specialty Channel

News
12Pb-DOTAMTATE Yields Durable and Deep Responses in PRRT-Naïve GEP-NETs
10/28/2025
Janelle Bradley
In the phase 2 ALPHAMEDIX 02 trial, 212Pb-DOTAMTATE produced a 57% objective response rate and durable disease control with a favorable safety profile in PRRT-naïve patients with advanced somatostatin receptor-positive GEP-NETs.
In the phase 2 ALPHAMEDIX 02 trial, 212Pb-DOTAMTATE produced a 57% objective response rate and durable disease control with a favorable safety profile in PRRT-naïve patients with advanced somatostatin receptor-positive GEP-NETs.
In the phase 2 ALPHAMEDIX 02...
10/28/2025
Radiopharmaceutical Education Institute
From Radiopharmaceutical Education Institute
News
212Pb-DOTAMTATE Achieves Durable Responses and Strong 2-Year Survival in GEP-NETs
10/20/2025
Janelle Bradley
The somatostatin receptor–targeted alpha therapy 212Pb-DOTAMTATE achieved durable, clinically meaningful responses and favorable survival outcomes in patients with unresectable or metastatic GEP-NETs naïve to peptide receptor radionuclide...
The somatostatin receptor–targeted alpha therapy 212Pb-DOTAMTATE achieved durable, clinically meaningful responses and favorable survival outcomes in patients with unresectable or metastatic GEP-NETs naïve to peptide receptor radionuclide...
The somatostatin...
10/20/2025
Oncology
Mohamed Shebl Abdelbaki, MD, Washington University of Medicine in St Louis
Videos
Latest Advances in Pediatric Low-Grade Gliomas
10/07/2025
Mohamed Shebl Abdelbaki, MD
Mohamed Shebl Abdelbaki, MD, gives a presentation on the latest advances in pediatric low-grade glioma.
Mohamed Shebl Abdelbaki, MD, gives a presentation on the latest advances in pediatric low-grade glioma.
Mohamed Shebl Abdelbaki, MD,...
10/07/2025
Oncology
News
Intratumoral Clostridium Novyi-Nontoxic Plus Pembrolizumab Demonstrates Clinical Promise Among Patients With Treatment-Refractory Advanced Solid Tumors
08/27/2025
Stephanie Holland
According to results from a phase 1b study, clostridium novyi-nontoxic plus pembrolizumab demonstrated clinical promise among patients with treatment-refractory advanced solid tumors.
According to results from a phase 1b study, clostridium novyi-nontoxic plus pembrolizumab demonstrated clinical promise among patients with treatment-refractory advanced solid tumors.
According to results from a...
08/27/2025
Oncology
Quiz
Camrelizumab Plus Apatinib for Patients With Advanced or Refractory Chordoma
08/14/2025
According to results from an investigator-initiated phase 2 trial, camrelizumab plus apatinib demonstrated promising efficacy and safety among patients with advanced or refractory chordoma. Biomarker analyses revealed which of the following...
According to results from an investigator-initiated phase 2 trial, camrelizumab plus apatinib demonstrated promising efficacy and safety among patients with advanced or refractory chordoma. Biomarker analyses revealed which of the following...
According to results from an...
08/14/2025
Oncology
News
Pencil Beam Scanning Proton Therapy Demonstrates Long-Term Clinical Efficacy, Safety Among Children and Adolescents With Chordomas or Chondrosarcomas
08/07/2025
Stephanie Holland
Study results demonstrated that curative pencil beam scanning proton therapy demonstrated promising long-term efficacy and safety among children and adolescent/young adult patients with chordomas or chondrosarcomas.
Study results demonstrated that curative pencil beam scanning proton therapy demonstrated promising long-term efficacy and safety among children and adolescent/young adult patients with chordomas or chondrosarcomas.
Study results demonstrated that...
08/07/2025
Oncology
News
Palbociclib Monotherapy Demonstrates Modest Clinical Activity Among Patients With Locally Advanced or Metastatic Chordoma
08/04/2025
Stephanie Holland
According to final results from the NCT PMO-1601 trial, palbociclib monotherapy demonstrated modest clinical activity among patients with locally advanced or metastatic chordoma.
According to final results from the NCT PMO-1601 trial, palbociclib monotherapy demonstrated modest clinical activity among patients with locally advanced or metastatic chordoma.
According to final results from...
08/04/2025
Oncology
Quiz
Sunitinib Plus Nivolumab for Patients With Advanced Extraskeletal Myxoid Chondrosarcoma
07/29/2025
True or False: According to results from the phase 2 IMMUNOSARC trial, sunitinib plus nivolumab demonstrated promising efficacy and safety among patients with advanced extraskeletal myxoid chondrosarcoma.
True or False: According to results from the phase 2 IMMUNOSARC trial, sunitinib plus nivolumab demonstrated promising efficacy and safety among patients with advanced extraskeletal myxoid chondrosarcoma.
True or False: According to...
07/29/2025
Oncology
News
Sunitinib Plus Nivolumab for Patients With Advanced Extraskeletal Myxoid Chondrosarcoma
07/23/2025
Stephanie Holland
According to results from the phase 2 IMMUNOSARC trial, sunitinib plus nivolumab demonstrated promising efficacy and safety among patients with advanced extraskeletal myxoid chondrosarcoma.
According to results from the phase 2 IMMUNOSARC trial, sunitinib plus nivolumab demonstrated promising efficacy and safety among patients with advanced extraskeletal myxoid chondrosarcoma.
According to results from the...
07/23/2025
Oncology
News
Camrelizumab Plus Apatinib Demonstrates Promise in Advanced or Refractory Chordoma
07/22/2025
Stephanie Holland
According to results from an investigator-initiated phase 2 trial, camrelizumab plus apatinib demonstrated promising efficacy and safety among patients with advanced or refractory chordoma.
According to results from an investigator-initiated phase 2 trial, camrelizumab plus apatinib demonstrated promising efficacy and safety among patients with advanced or refractory chordoma.
According to results from an...
07/22/2025
Oncology
Conference Coverage
Concurrent Temozolomide Plus Radiotherapy Fails to Improve Survival for Patients With Non-Codeleted Anaplastic Glioma
07/08/2025
Stephanie Holland
According to results from the phase 3 CATNON trial, concurrent temozolomide plus radiotherapy did not improve survival results compared to adjuvant temozolomide plus radiotherapy among patients without 1p/19p codeletion anaplastic glioma.
According to results from the phase 3 CATNON trial, concurrent temozolomide plus radiotherapy did not improve survival results compared to adjuvant temozolomide plus radiotherapy among patients without 1p/19p codeletion anaplastic glioma.
According to results from the...
07/08/2025
Oncology

News

News
12Pb-DOTAMTATE Yields Durable and Deep Responses in PRRT-Naïve GEP-NETs
10/28/2025
Janelle Bradley
In the phase 2 ALPHAMEDIX 02 trial, 212Pb-DOTAMTATE produced a 57% objective response rate and durable disease control with a favorable safety profile in PRRT-naïve patients with advanced somatostatin receptor-positive GEP-NETs.
In the phase 2 ALPHAMEDIX 02 trial, 212Pb-DOTAMTATE produced a 57% objective response rate and durable disease control with a favorable safety profile in PRRT-naïve patients with advanced somatostatin receptor-positive GEP-NETs.
In the phase 2 ALPHAMEDIX 02...
10/28/2025
Radiopharmaceutical Education Institute
News
212Pb-DOTAMTATE Achieves Durable Responses and Strong 2-Year Survival in GEP-NETs
10/20/2025
Janelle Bradley
The somatostatin receptor–targeted alpha therapy 212Pb-DOTAMTATE achieved durable, clinically meaningful responses and favorable survival outcomes in patients with unresectable or metastatic GEP-NETs naïve to peptide receptor radionuclide...
The somatostatin receptor–targeted alpha therapy 212Pb-DOTAMTATE achieved durable, clinically meaningful responses and favorable survival outcomes in patients with unresectable or metastatic GEP-NETs naïve to peptide receptor radionuclide...
The somatostatin...
10/20/2025
Oncology
News
Intratumoral Clostridium Novyi-Nontoxic Plus Pembrolizumab Demonstrates Clinical Promise Among Patients With Treatment-Refractory Advanced Solid Tumors
08/27/2025
Stephanie Holland
According to results from a phase 1b study, clostridium novyi-nontoxic plus pembrolizumab demonstrated clinical promise among patients with treatment-refractory advanced solid tumors.
According to results from a phase 1b study, clostridium novyi-nontoxic plus pembrolizumab demonstrated clinical promise among patients with treatment-refractory advanced solid tumors.
According to results from a...
08/27/2025
Oncology
News
Pencil Beam Scanning Proton Therapy Demonstrates Long-Term Clinical Efficacy, Safety Among Children and Adolescents With Chordomas or Chondrosarcomas
08/07/2025
Stephanie Holland
Study results demonstrated that curative pencil beam scanning proton therapy demonstrated promising long-term efficacy and safety among children and adolescent/young adult patients with chordomas or chondrosarcomas.
Study results demonstrated that curative pencil beam scanning proton therapy demonstrated promising long-term efficacy and safety among children and adolescent/young adult patients with chordomas or chondrosarcomas.
Study results demonstrated that...
08/07/2025
Oncology
News
Palbociclib Monotherapy Demonstrates Modest Clinical Activity Among Patients With Locally Advanced or Metastatic Chordoma
08/04/2025
Stephanie Holland
According to final results from the NCT PMO-1601 trial, palbociclib monotherapy demonstrated modest clinical activity among patients with locally advanced or metastatic chordoma.
According to final results from the NCT PMO-1601 trial, palbociclib monotherapy demonstrated modest clinical activity among patients with locally advanced or metastatic chordoma.
According to final results from...
08/04/2025
Oncology
News
Sunitinib Plus Nivolumab for Patients With Advanced Extraskeletal Myxoid Chondrosarcoma
07/23/2025
Stephanie Holland
According to results from the phase 2 IMMUNOSARC trial, sunitinib plus nivolumab demonstrated promising efficacy and safety among patients with advanced extraskeletal myxoid chondrosarcoma.
According to results from the phase 2 IMMUNOSARC trial, sunitinib plus nivolumab demonstrated promising efficacy and safety among patients with advanced extraskeletal myxoid chondrosarcoma.
According to results from the...
07/23/2025
Oncology
News
Camrelizumab Plus Apatinib Demonstrates Promise in Advanced or Refractory Chordoma
07/22/2025
Stephanie Holland
According to results from an investigator-initiated phase 2 trial, camrelizumab plus apatinib demonstrated promising efficacy and safety among patients with advanced or refractory chordoma.
According to results from an investigator-initiated phase 2 trial, camrelizumab plus apatinib demonstrated promising efficacy and safety among patients with advanced or refractory chordoma.
According to results from an...
07/22/2025
Oncology
Conference Coverage
Concurrent Temozolomide Plus Radiotherapy Fails to Improve Survival for Patients With Non-Codeleted Anaplastic Glioma
07/08/2025
Stephanie Holland
According to results from the phase 3 CATNON trial, concurrent temozolomide plus radiotherapy did not improve survival results compared to adjuvant temozolomide plus radiotherapy among patients without 1p/19p codeletion anaplastic glioma.
According to results from the phase 3 CATNON trial, concurrent temozolomide plus radiotherapy did not improve survival results compared to adjuvant temozolomide plus radiotherapy among patients without 1p/19p codeletion anaplastic glioma.
According to results from the...
07/08/2025
Oncology
Conference Coverage
Dordaviprone Demonstrates Clinical Promise for Patients With Recurrent H3 K27M-Mutated Diffuse Glioma
07/01/2025
Stephanie Holland
According to results from a phase 1/2 study, dordaviprone demonstrated clinical promise and safety among adult and pediatric patients with recurrent H3 K27M-mutated diffuse glioma.
According to results from a phase 1/2 study, dordaviprone demonstrated clinical promise and safety among adult and pediatric patients with recurrent H3 K27M-mutated diffuse glioma.
According to results from a...
07/01/2025
Oncology
News
Outcomes for Patients With Central Nervous System Tumors Harboring NTRK Gene Fusions
02/11/2025
Allison Casey
A retrospective study compared outcomes among pediatric and adult patients with central nervous system tumors with NTRK gene fusion based on tumor histology and type of treatment.
A retrospective study compared outcomes among pediatric and adult patients with central nervous system tumors with NTRK gene fusion based on tumor histology and type of treatment.
A retrospective study compared...
02/11/2025
Oncology

Interactive Features

Quiz
Camrelizumab Plus Apatinib for Patients With Advanced or Refractory Chordoma
08/14/2025
According to results from an investigator-initiated phase 2 trial, camrelizumab plus apatinib demonstrated promising efficacy and safety among patients with advanced or refractory chordoma. Biomarker analyses revealed which of the following...
According to results from an investigator-initiated phase 2 trial, camrelizumab plus apatinib demonstrated promising efficacy and safety among patients with advanced or refractory chordoma. Biomarker analyses revealed which of the following...
According to results from an...
08/14/2025
Oncology
Quiz
Sunitinib Plus Nivolumab for Patients With Advanced Extraskeletal Myxoid Chondrosarcoma
07/29/2025
True or False: According to results from the phase 2 IMMUNOSARC trial, sunitinib plus nivolumab demonstrated promising efficacy and safety among patients with advanced extraskeletal myxoid chondrosarcoma.
True or False: According to results from the phase 2 IMMUNOSARC trial, sunitinib plus nivolumab demonstrated promising efficacy and safety among patients with advanced extraskeletal myxoid chondrosarcoma.
True or False: According to...
07/29/2025
Oncology
Test Your Knowledge
Quiz: Is Large-Scale Outcome Data Currently Flawed in Brain Cancer Research?
01/12/2021
True or False: Although the combination of neurosurgical resection and postoperative HSRT is an emerging therapeutic approach for brain metastases, mature large-scale outcome data is currently lacking.
True or False: Although the combination of neurosurgical resection and postoperative HSRT is an emerging therapeutic approach for brain metastases, mature large-scale outcome data is currently lacking.
True or False: Although the...
01/12/2021
Oncology

Recent News

News
12Pb-DOTAMTATE Yields Durable and Deep Responses in PRRT-Naïve GEP-NETs
10/28/2025
Janelle Bradley
In the phase 2 ALPHAMEDIX 02 trial, 212Pb-DOTAMTATE produced a 57% objective response rate and durable disease control with a favorable safety profile in PRRT-naïve patients with advanced somatostatin receptor-positive GEP-NETs.
In the phase 2 ALPHAMEDIX 02 trial, 212Pb-DOTAMTATE produced a 57% objective response rate and durable disease control with a favorable safety profile in PRRT-naïve patients with advanced somatostatin receptor-positive GEP-NETs.
In the phase 2 ALPHAMEDIX 02...
10/28/2025
Radiopharmaceutical Education Institute
News
212Pb-DOTAMTATE Achieves Durable Responses and Strong 2-Year Survival in GEP-NETs
10/20/2025
Janelle Bradley
The somatostatin receptor–targeted alpha therapy 212Pb-DOTAMTATE achieved durable, clinically meaningful responses and favorable survival outcomes in patients with unresectable or metastatic GEP-NETs naïve to peptide receptor radionuclide...
The somatostatin receptor–targeted alpha therapy 212Pb-DOTAMTATE achieved durable, clinically meaningful responses and favorable survival outcomes in patients with unresectable or metastatic GEP-NETs naïve to peptide receptor radionuclide...
The somatostatin...
10/20/2025
Oncology
News
Intratumoral Clostridium Novyi-Nontoxic Plus Pembrolizumab Demonstrates Clinical Promise Among Patients With Treatment-Refractory Advanced Solid Tumors
08/27/2025
Stephanie Holland
According to results from a phase 1b study, clostridium novyi-nontoxic plus pembrolizumab demonstrated clinical promise among patients with treatment-refractory advanced solid tumors.
According to results from a phase 1b study, clostridium novyi-nontoxic plus pembrolizumab demonstrated clinical promise among patients with treatment-refractory advanced solid tumors.
According to results from a...
08/27/2025
Oncology
News
Pencil Beam Scanning Proton Therapy Demonstrates Long-Term Clinical Efficacy, Safety Among Children and Adolescents With Chordomas or Chondrosarcomas
08/07/2025
Stephanie Holland
Study results demonstrated that curative pencil beam scanning proton therapy demonstrated promising long-term efficacy and safety among children and adolescent/young adult patients with chordomas or chondrosarcomas.
Study results demonstrated that curative pencil beam scanning proton therapy demonstrated promising long-term efficacy and safety among children and adolescent/young adult patients with chordomas or chondrosarcomas.
Study results demonstrated that...
08/07/2025
Oncology
News
Palbociclib Monotherapy Demonstrates Modest Clinical Activity Among Patients With Locally Advanced or Metastatic Chordoma
08/04/2025
Stephanie Holland
According to final results from the NCT PMO-1601 trial, palbociclib monotherapy demonstrated modest clinical activity among patients with locally advanced or metastatic chordoma.
According to final results from the NCT PMO-1601 trial, palbociclib monotherapy demonstrated modest clinical activity among patients with locally advanced or metastatic chordoma.
According to final results from...
08/04/2025
Oncology
News
Sunitinib Plus Nivolumab for Patients With Advanced Extraskeletal Myxoid Chondrosarcoma
07/23/2025
Stephanie Holland
According to results from the phase 2 IMMUNOSARC trial, sunitinib plus nivolumab demonstrated promising efficacy and safety among patients with advanced extraskeletal myxoid chondrosarcoma.
According to results from the phase 2 IMMUNOSARC trial, sunitinib plus nivolumab demonstrated promising efficacy and safety among patients with advanced extraskeletal myxoid chondrosarcoma.
According to results from the...
07/23/2025
Oncology
News
Camrelizumab Plus Apatinib Demonstrates Promise in Advanced or Refractory Chordoma
07/22/2025
Stephanie Holland
According to results from an investigator-initiated phase 2 trial, camrelizumab plus apatinib demonstrated promising efficacy and safety among patients with advanced or refractory chordoma.
According to results from an investigator-initiated phase 2 trial, camrelizumab plus apatinib demonstrated promising efficacy and safety among patients with advanced or refractory chordoma.
According to results from an...
07/22/2025
Oncology
Conference Coverage
Concurrent Temozolomide Plus Radiotherapy Fails to Improve Survival for Patients With Non-Codeleted Anaplastic Glioma
07/08/2025
Stephanie Holland
According to results from the phase 3 CATNON trial, concurrent temozolomide plus radiotherapy did not improve survival results compared to adjuvant temozolomide plus radiotherapy among patients without 1p/19p codeletion anaplastic glioma.
According to results from the phase 3 CATNON trial, concurrent temozolomide plus radiotherapy did not improve survival results compared to adjuvant temozolomide plus radiotherapy among patients without 1p/19p codeletion anaplastic glioma.
According to results from the...
07/08/2025
Oncology
Conference Coverage
Dordaviprone Demonstrates Clinical Promise for Patients With Recurrent H3 K27M-Mutated Diffuse Glioma
07/01/2025
Stephanie Holland
According to results from a phase 1/2 study, dordaviprone demonstrated clinical promise and safety among adult and pediatric patients with recurrent H3 K27M-mutated diffuse glioma.
According to results from a phase 1/2 study, dordaviprone demonstrated clinical promise and safety among adult and pediatric patients with recurrent H3 K27M-mutated diffuse glioma.
According to results from a...
07/01/2025
Oncology
News
Outcomes for Patients With Central Nervous System Tumors Harboring NTRK Gene Fusions
02/11/2025
Allison Casey
A retrospective study compared outcomes among pediatric and adult patients with central nervous system tumors with NTRK gene fusion based on tumor histology and type of treatment.
A retrospective study compared outcomes among pediatric and adult patients with central nervous system tumors with NTRK gene fusion based on tumor histology and type of treatment.
A retrospective study compared...
02/11/2025
Oncology
News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT
01/26/2026
Gina Tomaine
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition...
01/26/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer
01/22/2026
Stephanie Holland
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3...
01/22/2026
Oncology
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use